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Abstract 
The first systems for continuous glucose monitoring (CGM) became available over 15 years 
ago. Many then believed CGM would revolutionize the use of intensive insulin therapy in 
diabetes; however, progress towards that vision has been gradual. Although increasing, the 
proportion of individuals using CGM rather than conventional systems for self-monitoring of 
blood glucose on a daily basis is still low in most parts of the world. Barriers to uptake include 
cost, measurement reliability (particularly with earlier generation systems), human factors 
issues, lack of a standardized format for displaying results, and uncertainty on how best to 
use CGM data to make therapeutic decisions. This Position Statement makes 
recommendations for systemic improvements in clinical usage and regulatory (pre- and post- 
marketing) handling of CGM devices. The aim is to improve safety and efficacy in order to 
support the advancement of the technology in achieving its potential to improve quality of life 
and health outcomes for more people with diabetes. 
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Introduction and Background 
Continuous glucose monitoring (CGM) is a method of continuously following glucose levels in 
the interstitial fluid as a basis for improving metabolic control.  This includes increasing time 
in the target glucose range by reducing hyperglycemia and minimizing the occurrence of low 
glucose values (including symptomatic hypoglycemia). The international diabetes community 
has welcomed the introduction of CGM systems.  However, daily use of these devices is 
associated with challenges including potential risks.  
 There are several ways in which CGM functions. It can either be blinded to the user 
or viewed in real-time. The device sends data continuously to a receiver, which allows for 
alerts and alarms to be provided to the wearer.  Recently a form of CGM known as “flash” 
glucose monitoring (Freestyle Libre, Abbott) became available from one manufacturer in 
some countries. Although this device is based on similar technology, daily costs are lower 
and no calibration is required but alarms are not provided for high and low glucose values. 
Interstitial glucose levels are measured continuously, but as data are not transmitted 
continuously from the sensor, the results are available only when the sensor is scanned with 
a reading device.  Full 24 hour data can be captured and downloaded if the sensor is 
scanned at least every eight hours. This latter form of CGM will be described here as 
intermittently-scanned continuous glucose monitoring (isCGM) (1). The glucose sensors of 
most CGM systems are inserted subcutaneously and worn externally by the user, although 
implantable CGM devices are also becoming available (2). 
Following an evaluation of insulin pumps (3), the same working group of the American 
Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) 
has now evaluated CGM and related technologies from a clinical perspective. The aim was 
not to replicate published position statements and overviews of CGM technology (4,5,6), but 
instead to consider how health care professionals, CGM manufacturers, regulatory 
authorities, policymakers and consumers can best ensure effective and appropriate use of 
CGM as the technology continues to develop. 
As only limited clinical trial data are required for approval of glucose monitoring 
devices, larger trials are often performed at a later stage with the aims of convincing payers 
to provide reimbursement and providing guidance on appropriate use. As such trials usually 
take three or more years, the marketed version of the CGM device has often been updated 
or modified by the time of publication. The rapidity of this development cycle means that a 
Position Statement can never be definitive nor comprehensive and requires regular updating.  
Our goal was to assess current clinical and regulatory aspects of CGM within this 
rapidly-evolving landscape in order to encourage cycles of improvement in device 
performance, clinical outcomes, and utilization. We make a number of recommendations 
(marked as numbers in rectangular brackets), each targeted at relevant stakeholders 
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involved in delivering safe and effective use of CGM. We gathered evidence by searching 
Pubmed from inception until end of November 2016 using the search terms “continuous 
glucose monitoring [Title/ Abstract] OR real-time glucose monitoring [Title/ Abstract] OR 
subcutaneous continuous glucose monitoring [Title/ Abstract] OR continuous measurement 
of glucose [Title/ Abstract].” We supplemented this with information from recent trial 
publications, abstracts, web-based resources, regulatory authorities (including from their 
databases), manufacturing companies and our own clinical experience. 
 
Clinical evidence 
Growing evidence supports the benefits of using CGM: the studies and clinical trials 
reviewed below suggest that adults with type 1 Diabetes (T1D) who wear CGM most days 
can improve glycemic control without increasing hypoglycemia, while those already close to 
target HbA1c can maintain control while reducing hypoglycemia. In children and adolescents, 
achieving adequate adherence remains a significant barrier, although usability has improved 
with current generation CGM devices in this age group [2b]. 
 
a) Type 1 Diabetes (T1D): In the JDRF trial, 322 adults and children (≥8 years of age) with 
HbA1c 7.0-10.0% (53-86 mmol/mol), more than 80% using continuous subcutaneous insulin 
infusion (CSII), were randomized to three different CGM devices (Dexcom SEVEN (Dexcom), 
MiniMed Paradigm Real-Time Insulin Pump and Continous Glucose-Monitoring System 
(Medtronic), Freestyle Navigator (Abbott Diabetes Care)) or usual self-monitoring of blood 
glucose (SMBG). A significant improvement in the primary outcome of change in HbA1c at 
26 weeks (-0.53%, 95% Confidence Intervals (CI) -0.71 to -0.35%) (-5.7 mmol/mol, 95% CI -
7.7, -3.8) was observed only in the subgroup defined by age ≥25 years. This improvement 
was strongly associated with wearing the device for six or more days per week (7). In the 
recent DIAMOND study, in which 158 adults on multiple daily injections (MDI) were 
randomized (2:1) to CGM (Dexcom G4) or usual care for six months, baseline HbA1c (8.6%) 
(70.5  mmol/mol) improved by 1.0% (11.0 mmol/mol) with CGM and by 0.4% (4.3 mmol/mol) 
with usual care (adjusted mean difference 0.6% (6.5 mmol/mol), p<0.001); adherence was 
high (8). A further large crossover trial is in progress using the same device (9) and 
supportive cross-sectional real world data are available (with the various marketed devices) 
(10). The potential for CGM to take the place of (rather than augment) SMBG recently gained 
support from (REPLACE-BG), an open-label randomized trial of 226 adults with well-
controlled T1D (HbA1c 7.1± 0.7% (54.0±7.6 mmol/mol) at baseline) that compared “CGM 
only” with “CGM and SMBG”: SMBG in addition to CGM had no effect on time in range (70-
180 mg/dL)(3.9-10.0 mmol/L), the primary endpoint (11).  For this reason, the FDA recently 
(December 2016) approved a specific CGM device (Dexcom G5® Mobile CGM System) to 
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replace fingerstick glucose measurements in people with diabetes two years of age or older, 
although twice daily fingerstick calibrations remain necessary (12).  
Some evidence with isCGM is also now available in T1D. In the recent IMPACT trial, 
241 adults with T1D and HbA1c ≤7.5% (58.5 mmol/mol) (68% treated with MDI; 32% with 
CSII) wore an isCGM device for 14 days (Abbott Freestyle Libre) without access to glucose 
results. This period was then compared with a subsequent 14-day period when access to 
data was provided. The primary endpoint of time spent in hypoglycemia (<70 mg/dL)(<3.9 
mmol/L) was reduced by almost 90 minutes per day (p<0.0001) with isCGM while time in 
hyperglycemia (>240 mg/dL)(>13.3 mmol/L) was also reduced by just over 20 minutes per 
day (p=0.0247); there was no change in HbA1c over this short period (13). 
b) Type 2 Diabetes (T2D): Currently there is limited evidence to support the use of CGM in 
this large group of individuals: further studies are required [4a, 4b]: In a single center 
controlled trial (RCT) which randomized 100 people with T2D on a variety of therapies 
(excluding prandial insulin) to either SMBG or intermittent use of CGM (Dexcom SEVEN), a 
significant improvement in HbA1c from a baseline of 8.3% (67.2 mmol/mol) was observed 
over 12 weeks for CGM vs SMBG (1.01.1 vs 0.50.8%)(11.012.0 vs 5.48.7 mmol/mol) 
(14). The improvement was sustained (although attenuated) over a 40-week observational 
follow-up period (0.81.5 vs 0.21.3%)(8.716.3 vs 2.114.1 mmol/mol) (15). These data 
require replication using other CGM devices and in other populations with T2D, but provide 
support for periodic use of CGM in those using basal insulin (16).  
In the case of isCGM, a six-month trial (REPLACE, Abbott Freestyle Libre) in people 
with T2D on basal-bolus insulin therapy and a baseline HbA1c of 8.8% (72.7 mmol/L) 
showed a significant reduction in time in hypoglycemia (by almost 30 minutes), but no 
change in HbA1c, the primary endpoint (17). 
 The above mentioned clinical studies have undoubtedly moved the field forward, but 
our review of the CGM literature revealed common design limitations, including:  
(i) Few studies (18) including individuals with a recent history of severe hypoglycemia [4a] 
(ii) Few head-to-head comparisons (19) between CGM systems [3e, 4a],  
(iii) Lack of standardization of outcome measures for glycemic control and glucose variability 
[1c], an issue recently highlighted at an FDA workshop (20)  
(iv) Lack of consensus on appropriate patient reported outcomes (PRO) (21-23) [1d, 2e, 3c] 
(v) Insufficient statistical power to detect important outcomes (i.e. insufficient study duration/ 
sample size) [2e, 3e] 
(vi) Lack of a standard reporting format for CGM data [1c, 2a] 
(vii) Insufficient guidance for participants on how best to make therapeutic decisions on the 
basis of CGM data [5c] 
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(viii) Lack of adequate masking between active and comparator arms (with potential for a 
research participation or “Hawthorne” effect) (24) [4a] 
 
Meta-analyses 
A number of formal summaries of the CGM literature have been conducted (25-32). Although 
this suggests that the field is coming of age, review of the existing evidence base has 
generated diverse conclusions, ranging from "limited evidence" (Cochrane review) (26) to 
fully supportive (28-30). In only two of the meta-analyses have individual patient level data 
been combined: both of these showed a small improvement in HbA1c with no change in 
rates of hypoglycemia (4, 28). The others used mean values and took different approaches 
to inclusion and exclusion criteria, pooled data from CGM systems with different performance 
characteristics, and/or focused on studies financed by particular manufacturers (27). 
The heterogeneity of the outcome of the meta-analyses performed indicates that a more 
standardized and systematic approach (33) is required to avoid reaching inappropriate 
conclusions that could undermine the value of CGM [2f].  
 
Design and remaining limitations of CGM systems 
The design of most CGM systems has improved markedly over the years. For example, 
changes which are fundamental from a safety perspective have occurred at least in part 
because the FDA and other regulatory authorities began to require human factor studies 
prior to market approval (34) [1a, 3b]: these include more accurate glucose measurement, 
more audible alarms, and easier to read displays.  
 The remaining limitations can be grouped as follows: 
Technical issues: 
- Measurement of capillary blood glucose levels using a standard SMBG system is 
currently required for initial calibration and regular daily re-calibrations for all devices 
except isCGM. 
- Episodic differences in sensor performance can be observed in the same individual (may 
or may not be attributable to the technology) 
- Sensors are approved for use for only varying lengths of time, with implantable sensors 
lasting longest 
User issues: 
- Wearing a device continuously can be a burden 
- A skin puncture is required each time for insertion of the glucose sensor into the 
subcutaneous skin tissue (or a small surgical procedure for an implantable device) 
- Limited scope to personalize the user interface [2b] 
Safety issues 
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- Site reactions, skin rashes (to adhesives), pulling off, falling off, sweating off, losing 
transmitter, receiver, issues with transmission at night, malfunctioning sensors, silencing 
of alarms if smart phone is on vibrate or silent mode are frequently reported. [1a, 2g]  
Costs 
- High costs for sensors and replacing system components  
- In some settings, prohibitive amounts of paperwork to obtain approval for coverage 
Optimizing the technology to overcome as many of these issues as possible requires a high 
level of cooperation [5d] between all relevant stakeholders: regulatory agencies, 
manufacturing companies, academic researchers, research funding bodies, health 
professionals, medical associations, and patient groups (as per the specific 
recommendations below). 
 
Combination of CGM with insulin pumps: automated insulin delivery 
A number of different combinations of CGM systems with insulin pumps are available on the 
market in the EU and more recently in the US. Trends towards reductions in the occurrence 
of mild and severe hypoglycemic events when using such combinations have been reported 
(35, 36), but also challenged (37). These represent an intermediate step towards automated 
insulin delivery (AID) systems (38): rapid development has led to the recent market approval 
and launch of the first hybrid closed loop system (Minimed 670G (Medtronic)) (39).  
Reliable CGM system performance with accurate, uninterrupted glucose information 
is a key component of a safe and effective performance of any such AID systems, i.e. 
ongoing automated adjustment of subcutaneous insulin infusion (with or without glucagon) 
according to ambient glucose levels. However, if there is an undetected malfunction, missing 
data transfer, or the algorithms do not handle the CGM data adequately, a clinically relevant 
adverse event can clearly ensue [3a]. As with CGM, there are likely to be rapid 
improvements in AID systems from one generation to the next that will challenge the pace of 
clinical evaluation (see above) and ask for standardized outcome measures (19-21) [1c]. 
 
Glucose measurement in interstitial fluid 
The glucose sensors of CGM systems measure glucose in interstitial fluid as opposed to 
SMBG which measures glucose in capillary blood. Although few formal studies have been 
published with modern sensors, the assumption that interstitial glucose measurement results 
can be calibrated to capillary blood glucose accurately and reliably used as a basis for 
therapeutic decisions may be less warranted during periods of rapid changes in glycemia. In 
the post-absorptive state, there are measurable differences between capillary blood and 
interstitial fluid glucose.  A study published in 2003 estimated that at an ambient glucose 
around 200 mg/dL, change in interstitial glucose over time was 15% lower when glucose 
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was increasing and 20% higher when glucose was decreasing [3a] (40). Such 
discrepancies between blood and interstitial fluid are potentially compounded by both 
physiological and “instrumental” time delay (i.e. while the measurement takes place) (39) and 
also by exercise. Adjusting the insulin dose on the basis of CGM glucose values therefore 
carries - at least a theoretical - risk of over- or underestimation with obvious attendant risks 
(41). However, despite these concerns, interstitial glucose concentrations from CGM appear 
sufficiently robust for successful use with AID systems (38, 39), and recent data suggest 
increased time in target when insulin dosing decisions are taken on the basis of CGM as 
opposed to SMBG (11). Time trends in glucose concentrations may be more informative than 
infrequent single time point estimates using SMBG, even if the latter are more accurate from 
an analytical point of view. 
 
Data handling and reporting 
At present, each manufacturer of CGM systems has its own format for display of glucose 
data. In addition, there are a number of tools in use for data display and analysis [e.g. 
Glooko/ Diasend (these two companies merged in 2016), Tidepool]. From a user and clinical 
perspective, a key aspect is how much time a given individual spent in a defined glucose 
range i.e. time in range (TIR). While individualized ranges may be appropriate for some 
individuals and situations, we believe that a standard and universal definition range for 
glucose TIR [e.g. 70-180 mg/dl (3.9-10.0 mmo/L)] would be desirable as an endpoint for 
clinical trials. However, a number of other parameters are in current use for characterization 
of:  
(a) glucose control – mean glucose (of all readings), median glucose for all readings, area 
under the curve (AUC) [for 24 hours, normalized hourly, excess for 24 hours], low blood 
glucose index (LBGI); and  
(b) glucose variability - total standard deviation (SD) [within-day or between-day], 
interquartile range (IQR), co-efficient of variation (CV), mean amplitude of glucose 
excursions (MAGE), mean of daily difference (MODD) and continuous overall net glycemic 
action (CONGA) and others have been described (20, 41, 42). As stated above, reporting 
results from CGM trials with these diverse and non-standardized measures prevents robust 
comparisons between and amongst studies, hampers meta-analyses, and complicates 
interpretation of the evidence by payers and regulatory agencies [1d]. The Ambulatory 
Glucose Profile (AGP) has been recommended as a potential universal software report that 
could be adopted to standardize summary metrics amongst devices and manufacturers (43).  
As with regular blood glucose meters, in daily practice most CGM users never 
actually download data from their devices (10). No systematic evaluations have been 
reported on the information most often used in daily life to guide insulin adjustment decisions: 
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i.e. whether individuals with diabetes mostly rely for decisions on insulin dose adjustment on 
the current glucose value, the glucose profile over the previous few hours, or the “trend 
arrow” (which indicates when the blood glucose is rapidly falling or rising but differs in format 
between devices) (44,45). [3e] 
 
Safety of CGM usage 
Scientific knowledge concerning the safety of CGM usage in daily life is limited. Many 
interesting user comments on safety aspects of CGM systems can be found on internet 
blogs, but are of limited generalizability. The manufacturers (as with insulin pumps and other 
medical devices) are required by the regulatory agencies to collect and report the customer 
complaints they receive for their product. However, the total number of CGM users is 
unknown as the numbers sold and operating are not currently reported (i.e. there is no 
denominator) and data are not reported in formats that are sufficiently consistent or easily 
searchable to be helpful in improving safety. 
For example, on the FDA database for medical devices (MAUDE), issues attributed to 
user error cannot be filtered from those considered potentially device-related. A search for 
reports involving “Enlite” or Dexcom (as examples of specific CGM systems) showed quite 
different results. Problems specific to CGM systems such as skin reactions, sensor failure or 
hypoglycemia are not searchable terms. As the database can be searched by “event type” 
(death, injury, malfunction, other) and due to our focus on safety, we searched under “death” 
and “injury”, restricting to one month each year due to the large number of monthly events 
listed.  
From Table 2, it is clear that reporting procedures for these two device manufacturers 
differ substantially and change over time. Many of the reports of death could not have been 
related to the CGM systems as the harmed individual was not wearing the glucose sensor at 
the time of death, but were notified by the manufacturer as CGM supplies were no longer 
required. Although we found several reports of death due to hypoglycemia while wearing a 
CGM system, none were considered a device issue. 
Our working group initiated discussions with the FDA with a view to reaching a better 
understanding of current safety reporting procedures. The FDA was willing to communicate 
directly with us but as the responsibility for reporting customer and complaints rests with 
individual device companies, we did not obtain any data additional to those already publicly 
available via MAUDE. [2c] 
We also sent a set of five questions to the four CGM system manufacturing 
companies: Medtronic, Dexcom, Abbott and Roche. All provided complete and informative 
responses. The most interesting variation was in response to the question (“most common 
patient complaints reported through FDA’s MAUDE system”): while one company provided 
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specific answers, another replied that it considered this information confidential. In our view, 
this latter approach illustrates a fundamental impediment to improving the safety of CGM 
systems: if safety data reported for regulated health products are considered proprietary and 
are not made publicly-available, a cycle of safety improvement cannot occur. [1f, 2c] 
 
Education and training  
CGM is primarily a diagnostic technique and cannot be expected to improve glucose control 
per se any more than weighing scales can be expected to reduce weight. Without 
appropriate training, users of CGM may not be able to make optimal usage of the information 
provided.  
Even in diabetes clinics, CGM data may not be optimally used. For example, 
physicians and other healthcare workers may vary in familiarity with the different approaches 
used in the different systems and/or data interpretation software available from each 
manufacturer [5b]. In addition, time and/ or financial constraints often do not permit sufficient 
discussion with individuals, so that the potential benefit of CGM is often not achieved. 
To date, as most training programs have been developed and delivered by 
manufacturing companies, they focus on technical aspects of their own products rather than 
optimal usage of CGM as a technology to improve diabetes therapy. Training is not routinely 
available either to providers or users on how to react to the measurement results, either in 
real time or retrospectively and few programs have been systematically evaluated to 
determine their effectiveness. There are only a few company-independent teaching programs 
[SPECTRUM in Germany (46), AID Training Program in the US (47), and one website (42, 
48)] supporting visualization and analysis of glucose data from SMBG, CGM and isCGM [2d, 
5b, 5c]. isCGM is increasingly being used without training because it can be ordered direct 
from the manufacturer online and be used without input from health care professionals; 
however, a training program is under development. 
 
Cost-benefit and reimbursement 
At present, costs of CGM are reimbursed for people with type 1 (but not type 2) diabetes <65 
years of age by most commercial insurance companies in the US.   In the US, following the 
FDA ruling in December 2016, Medicare Ruling 1682R in January 2017 approved coverage 
of “therapeutic CGM” (i.e. to replace fingerstick testing) in insulin treated individuals with type 
1 and type 2 diabetes (using the Dexcom G5) (49). In Europe CGM is reimbursed in only a 
few countries (including Germany).(50, 51). This heterogeneous coverage also reflects the 
weaknesses and gaps in clinical evidence highlighted above. The few formal cost-benefit 
studies that have been published are open to interpretation and sensitive to assumptions 
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made in the underlying models (51,52) [1e, 3d]. Perhaps not surprisingly, CGM studies 
supported by manufacturers are more supportive than those performed by payers. However, 
some companies perform studies by providing funds and devices to an independent site that 
acts as a coordinating center and has independent oversight of the trial conduct and data 
analysis. 
 
Remote usage of CGM data: opportunities and challenges 
Having realized the potential of remotely accessed CGM for monitoring their children’s 
glucose control when away at school or university, and frustrated that no commercial devices 
offering this facility had reached the market until recently (53), some parents of children with 
type 1 diabetes developed custom-made solutions by “hacking” commercially-available CGM 
products and releasing code for other users (www.nightscout.com) (54). [2g] While the 
underlying motivation is completely understandable and will likely stimulate larger companies 
to continue to innovate, such informal solutions raise safety concerns and present a 
challenge for the regulatory establishment as open source software is not regulated by 
regulatory agencies like the FDA. There are also issues of privacy and consent. [1g,2h] 
 The Nightscout community continues to grow on Facebook, although the first cloud-
based CGM systems with remote connectivity are now commercially available. Such remote 
support is not reimbursed but, insofar as they are used, manufacturers increasingly have the 
capacity and means to interact directly with users, supporting sharing of measured glucose 
values with health care professionals, and learning from anonymized “big” data (55). This 
approach has enormous potential, but automatic downloading of CGM results on servers 
owned by manufacturers also carries risks and complexities in terms of liability, consent, 
privacy and data protection (56). Use of CGM in school settings is a new challenge to be 
addressed. Due to differences in legal tradition, there is higher sensitivity on these issues in 
Europe, particularly when data are transferred across national boundaries to largely US-
based manufacturers. Guidance on cybersecurity of medical devices has recently been 
published (57) and the use of an international data “safe harbor” has been proposed as a 
solution (58). [1g, 2h]   
 
Use of CGM for therapeutic product development and regulatory purposes in 
clinical trials 
In clinical trials the roles of SMBG and CGM technologies substantially overlap. CGM has 
great potential for supporting clinical development of e.g. new insulin products and other 
glucose-lowering agents in people with both type 1 and type 2 diabetes. Analysis of 
continuously registered glucose profiles provides much more information about the impact of 
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drugs on ambient glucose levels than any form of episodic SMBG (e.g. 7-point glucose 
profiles). For example, frequency of nocturnal or total daily hypoglycemic events as 
determined by CGM could be used as clinical trial endpoints [1d]: no other feasible 
alternative technology for accessing nocturnal hypoglycemia is available. For CGM to 
provide evaluable endpoints, consensus on definitions of the various levels of time in range 
and hypoglycemia (in clinical practice and by CGM) is urgently required amongst payers and 
providers (21, 43). On this topic there has been some very recent progress (59). 
 If the FDA and other regulators were to accept such consensus definitions, CGM 
could have significant impact on the development and refining of new diabetes treatment 
options. The same technology could be used for better studies of physiology and 
pathophysiology, e.g. understanding glucose metabolism during exercise and feeding in 
health and disease. A virtuous cycle could be created with increasing evidence for the value 
of monitoring technologies, improvement in these technologies, and demonstration of the 
favorable economics of wider availability. FDA’s Center for Drug Evaluation and Research 
(CDER), which regulates drug therapies, recently examined new definitions and standards 
for measuring glycemia and other patient reported outcomes beyond HbA1c in clinical trials 
and expressed willingness to continue a series of meeting in an attempt to reach a 
consensus (21). FDA’s Center for Devices and Radiologic Health (CDRH), which regulates 
devices and diagnostics, is supportive of the use of data from appropriately standardized 
CGM devices for clinical trials, as it has approved numerous trials using devices that regulate 
insulin delivery based on CGM values (36, 39, 60). CDRH has generally requested that 
investigators utilize the key glucose outcome metrics outlined by Maahs et al. in the 
consensus report on artificial pancreas outcome measures for clinical trials (21). 
 
Conclusions and outlook 
Great progress has been made in CGM technology in recent years (61), but several barriers 
remain before it can reach its full potential either as a method for improving glycemic control 
in diabetes (with sufficient rigor for payers to reimburse), or as a means of assessing the 
efficacy of diabetes therapies (e.g. a novel insulin potentially associated with less 
hypoglycemia).  
Insufficient evidence of clinical utility and reliability and the lack of consistent 
reimbursement contributes to limited use of CGM across large populations of people with 
diabetes who could potentially benefit. A more concerted commitment to seeking robust 
evidence by industry, regulators, clinical and technical experts, as well as funding and patient 
organizations is necessary for the necessary trials to be conducted and for the field to 
progress.  
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CGM is a critically important technology for enabling AID systems. With further 
confirmation of the safety and utility of freestanding CGM technology, a more widespread 
uptake might be achieved.  
Our recommendations can be categorized under the following themes: 
 More systematic and structured pre-marketing evaluation of the performance of CGM 
systems [1a, 1b] 
 Greater investment in trials to provide evidence of CGM value and reliability for all 
patient groups [4a, 4b] 
 Standardization of CGM-measured glucose data reporting from clinical trials [1c] 
 Improved consistency and accessibility of safety reports to regulatory authorities after 
market approval  
 Increased communication and cooperation across stakeholder groups [2h] 
We envision an ongoing role of ADA, EASD, and other professional medical associations in 
supporting the virtuous cycle of CGM innovation, confirmation of value to users, increased 
utilization, and greater resources reinvested to support innovation. For this vision to be 
realized without further delay, we call upon regulators and manufacturing companies to work 
urgently with health professionals and people with diabetes to create an environment with 
much greater standardization of outcome measures, a high level of attention to safety issues, 
and full transparency of adverse event reporting. 
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Recommendations: 
 
A high level of cooperation and engagement is required amongst the following 
stakeholders. Specifically, we recommend: 
 
1) Regulatory agencies should: 
a) Introduce a systematic, independent and structured pre-marketing and post approval 
evaluation of the performance of CGM systems including assessment of “human factors” 
b) Promote the development of a consensus on which parameters should be analyzed and 
reported to characterize the performance of a CGM system 
c) Specify a standardized CGM output format for reporting time in range and hypoglycemia 
for use in clinical trials 
d) Review available outcomes measures (including patient-related outcomes) and specify 
those best used in CGM and AID studies  
e) Assess available models for cost-benefit calculations and specify which should be used 
for CGM studies 
f) Rapidly and transparently disseminate safety-related data reports on CGM to healthcare 
professionals 
g) Protect the security and confidentiality of patient data in the era of connectivity  
 
2) Manufacturing companies should: 
a) Cooperate to standardize output formats ± software used for analysis  
b) Provide interfaces that can be personalized according to the needs of the user 
c) Report all safety related data transparently to the regulatory authorities 
d) Cooperate with academia and healthcare professionals on providing balanced and 
adequate information to people with diabetes and package the output data in 
standardized formats to make it easy for major electronic health record (EHR) 
companies to access and incorporate for clinical use. 
e) Incorporate a wider range of existing outcome measures including patient-reported 
outcomes in study designs of adequate statistical power 
f) Publish all relevant data / information collected during the clinical development of a given 
CGM system, e.g. the results of Human Factor studies.  
g)  Communicate frequently and regularly with users, user groups and families affected by 
diabetes in order that real needs can be identified and promptly addressed as soon as 
the relevant technology becomes available (e.g. remote monitoring) 
h)  Observe high standards of data security and patient confidentiality 
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3) Researchers/ academics should: 
a) Develop better algorithms to improve the performance of CGM and AID systems  
b) Openly report and share the patient level results of all clinical studies 
c) Develop and validate specific and appropriate patient-related outcome measures 
d) Develop better models for cost-benefit analyses (in partnership with industry and 
regulatory bodies) 
e) Work to develop and perform studies that fill genuine "gaps" in the evidence 
f) Follow the recommendations made by Pickup (33) when interpreting or performing meta-
analyses [including 3) b)], 
g) Involve people with diabetes and their family members/caregivers in the development of 
CGM and AID systems for guidance and feedback. 
 
4) Research funding bodies should: 
a) Fund fewer small, underpowered studies of specific devices; instead well-designed 
larger "class" studies with clinically relevant endpoints using more than one CGM system 
and including head-to-head comparisons 
b) Fund large independent registry studies. 
 
5) Patient groups, health professionals, and medical associations should: 
a) Provide and regularly update recommendations on CGM. 
b) Provide minimum standards of training for providers and people with diabetes using 
CGM, isCGM, and AID 
c) Work to develop and disseminate structured company-independent education programs 
e.g. SPECTRUM and standardized output of glucose metrics and glucose and insulin 
profiles e.g. Ambulatory Glucose Profile (AGP). 
d)  Work together (AACE, AADE, ADA, EASD, Endocrine Society, IDF, ISPAD, JDRF and 
other patient advocacy groups) to provide wider access to CGM for all people with 
diabetes who are willing and able to use these devices on a near daily basis 
 
6)  Consumers of CGM technology—patients, family members, caregivers—should: 
a)  Report device errors and malfunctions to the manufacturers and appropriate regulatory 
agencies  
b)  Provide input to the policy development processes of professional and patient advocacy 
associations and regulatory authorities  
c)  Advocate for standardization and improved accessibility of CGM safety data to facilitate 
product comparisons. 
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Table 1 
Search results from the MAUDE database of the FDA (number of hits) 
 
 Dexcom    Enlite    
 Jul 
2013 
Jul 
2014 
Jul 
2015 
Jul 
2016 
Jul 
2013 
Jul 
2014 
Jul 
2015 
Jul 
2016 
All 31 1979 3564 7453 0 492 366 302 
         
Injury 20 31 78 167 0 34 163 6 
         
Death 0 0 8 10 0 0 0 0 
         
Adverse events are not necessarily caused by the device. N.B. these data cannot be 
used to compare devices due different practices in reporting of adverse events (as 
discussed under heading "Safety of CGM usage).  
